These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2885701)
1. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Murphy WA; Lance VA; Moreau S; Moreau JP; Coy DH Life Sci; 1987 Jun; 40(26):2515-22. PubMed ID: 2885701 [TBL] [Abstract][Full Text] [Related]
2. Superactive octapeptide somatostatin analogs containing tryptophan at position 1. Cai RZ; Karashima T; Guoth J; Szoke B; Olsen D; Schally AV Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2502-6. PubMed ID: 2882520 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Cai RZ; Szoke B; Lu R; Fu D; Redding TW; Schally AV Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1896-900. PubMed ID: 2869490 [TBL] [Abstract][Full Text] [Related]
4. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Karashima T; Cai RZ; Schally AV Life Sci; 1987 Aug; 41(8):1011-9. PubMed ID: 2886886 [TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Schally AV; Redding TW Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164 [TBL] [Abstract][Full Text] [Related]
6. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV Prostate; 1992; 20(4):297-310. PubMed ID: 1351672 [TBL] [Abstract][Full Text] [Related]
7. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Konturek SJ; Bilski J; Jaworek J; Tasler J; Schally AV Proc Soc Exp Biol Med; 1988 Feb; 187(2):241-9. PubMed ID: 2448802 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of receptors for somatostatin in various tumors using different analogs. Srkalovic G; Cai RZ; Schally AV J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467 [TBL] [Abstract][Full Text] [Related]
10. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion. Murphy WA; Taylor JE; Moreau JP; Coy DH Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697 [TBL] [Abstract][Full Text] [Related]
11. A super active cyclic hexapeptide analog of somatostatin. Veber DF; Saperstein R; Nutt RF; Freidinger RM; Brady SF; Curley P; Perlow DS; Paleveda WJ; Colton CD; Zacchei AG Life Sci; 1984 Apr; 34(14):1371-8. PubMed ID: 6143233 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin antagonist analog increases GH, insulin, and glucagon release in the rat. Fries JL; Murphy WA; Sueiras-Diaz J; Coy DH Peptides; 1982; 3(5):811-4. PubMed ID: 6129618 [TBL] [Abstract][Full Text] [Related]
13. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Zalatnai A; Paz-Bouza JI; Redding TW; Schally AV Prostate; 1988; 12(1):85-98. PubMed ID: 2894651 [TBL] [Abstract][Full Text] [Related]
14. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Szepeshazi K; Lapis K; Schally AV Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of a nonreducible cyclic analog of somatostatin having only growth hormone release inhibiting activity. Garsky VM; Clark DE; Grant NH Biochem Biophys Res Commun; 1976 Dec; 73(4):911-6. PubMed ID: 15625860 [TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous or intracerebroventricular injections of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on GH release in conscious, freely moving male rats. Yagi H; Kaji H; Sato M; Okimura Y; Chihara K Neuroendocrinology; 1996 Feb; 63(2):198-206. PubMed ID: 9053785 [TBL] [Abstract][Full Text] [Related]
20. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]